Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 82

1.

The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology.

van Bilsen M, Patel HC, Bauersachs J, Böhm M, Borggrefe M, Brutsaert D, Coats AJS, de Boer RA, de Keulenaer GW, Filippatos GS, Floras J, Grassi G, Jankowska EA, Kornet L, Lunde IG, Maack C, Mahfoud F, Pollesello P, Ponikowski P, Ruschitzka F, Sabbah HN, Schultz HD, Seferovic P, Slart RHJA, Taggart P, Tocchetti CG, Van Laake LW, Zannad F, Heymans S, Lyon AR.

Eur J Heart Fail. 2017 Nov;19(11):1361-1378. doi: 10.1002/ejhf.921. Epub 2017 Sep 26.

PMID:
28949064
2.

Inhibitory actions of the NRG-1/ErbB4 pathway in macrophages during tissue fibrosis in the heart, skin, and lung.

Vermeulen Z, Hervent AS, Dugaucquier L, Vandekerckhove L, Rombouts M, Beyens M, Schrijvers DM, De Meyer GRY, Maudsley S, De Keulenaer GW, Segers VFM.

Am J Physiol Heart Circ Physiol. 2017 Nov 1;313(5):H934-H945. doi: 10.1152/ajpheart.00206.2017. Epub 2017 Aug 19.

PMID:
28822966
3.

The future of pleiotropic therapy in heart failure. Lessons from the benefits of exercise training on endothelial function.

De Keulenaer GW, Segers VFM, Zannad F, Brutsaert DL.

Eur J Heart Fail. 2017 May;19(5):603-614. doi: 10.1002/ejhf.735. Epub 2017 Jan 19. Review.

PMID:
28105791
4.

A novel set-up for the ex vivo analysis of mechanical properties of mouse aortic segments stretched at physiological pressure and frequency.

Leloup AJ, Van Hove CE, Kurdi A, De Moudt S, Martinet W, De Meyer GR, Schrijvers DM, De Keulenaer GW, Fransen P.

J Physiol. 2016 Nov 1;594(21):6105-6115. doi: 10.1113/JP272623. Epub 2016 Aug 2.

5.

ErbB2 signaling at the crossing between heart failure and cancer.

Vermeulen Z, Segers VF, De Keulenaer GW.

Basic Res Cardiol. 2016 Nov;111(6):60. doi: 10.1007/s00395-016-0576-z. Epub 2016 Sep 5. Review.

6.

Neuregulin-1 attenuates development of nephropathy in a type 1 diabetes mouse model with high cardiovascular risk.

Vandekerckhove L, Vermeulen Z, Liu ZZ, Boimvaser S, Patzak A, Segers VF, De Keulenaer GW.

Am J Physiol Endocrinol Metab. 2016 Apr 1;310(7):E495-504. doi: 10.1152/ajpendo.00432.2015. Epub 2016 Jan 19.

7.

Myocardial Microvascular Inflammatory Endothelial Activation in Heart Failure With Preserved Ejection Fraction.

Franssen C, Chen S, Unger A, Korkmaz HI, De Keulenaer GW, Tschöpe C, Leite-Moreira AF, Musters R, Niessen HW, Linke WA, Paulus WJ, Hamdani N.

JACC Heart Fail. 2016 Apr;4(4):312-24. doi: 10.1016/j.jchf.2015.10.007. Epub 2015 Dec 9.

PMID:
26682792
8.

Neuregulin-1 improves right ventricular function and attenuates experimental pulmonary arterial hypertension.

Mendes-Ferreira P, Maia-Rocha C, Adão R, Mendes MJ, Santos-Ribeiro D, Alves BS, Cerqueira RJ, Castro-Chaves P, Lourenço AP, De Keulenaer GW, Leite-Moreira AF, Brás-Silva C.

Cardiovasc Res. 2016 Jan 1;109(1):44-54. doi: 10.1093/cvr/cvv244. Epub 2015 Oct 26.

PMID:
26503987
9.

Effect of angiotensin II-induced arterial hypertension on the voltage-dependent contractions of mouse arteries.

Fransen P, Van Hove CE, Leloup AJ, Schrijvers DM, De Meyer GR, De Keulenaer GW.

Pflugers Arch. 2016 Feb;468(2):257-67. doi: 10.1007/s00424-015-1737-x. Epub 2015 Oct 3.

PMID:
26432297
10.

Chronic intermittent mental stress promotes atherosclerotic plaque vulnerability, myocardial infarction and sudden death in mice.

Roth L, Rombouts M, Schrijvers DM, Lemmens K, De Keulenaer GW, Martinet W, De Meyer GR.

Atherosclerosis. 2015 Sep;242(1):288-94. doi: 10.1016/j.atherosclerosis.2015.07.025. Epub 2015 Jul 15.

PMID:
26233915
11.

Letter by Brutsaert and De Keulenaer Regarding Article, "Effects of Sildenafil on Ventricular and Vascular Function in Heart Failure With Preserved Ejection Fraction".

Brutsaert DL, De Keulenaer GW.

Circ Heart Fail. 2015 Jul;8(4):839. doi: 10.1161/CIRCHEARTFAILURE.115.002236. No abstract available.

12.

Cardiac endothelium-myocyte interaction: clinical opportunities for new heart failure therapies regardless of ejection fraction.

Lim SL, Lam CS, Segers VF, Brutsaert DL, De Keulenaer GW.

Eur Heart J. 2015 Aug 14;36(31):2050-2060. Epub 2015 Apr 23. Review.

PMID:
25911648
13.

Left ventricular diastolic dysfunction and myocardial stiffness in diabetic mice is attenuated by inhibition of dipeptidyl peptidase 4.

Hamdani N, Hervent AS, Vandekerckhove L, Matheeussen V, Demolder M, Baerts L, De Meester I, Linke WA, Paulus WJ, De Keulenaer GW.

Cardiovasc Res. 2014 Dec 1;104(3):423-31. doi: 10.1093/cvr/cvu223. Epub 2014 Oct 23.

PMID:
25341892
14.

Applanation tonometry in mice: a novel noninvasive technique to assess pulse wave velocity and arterial stiffness.

Leloup AJ, Fransen P, Van Hove CE, Demolder M, De Keulenaer GW, Schrijvers DM.

Hypertension. 2014 Jul;64(1):195-200. doi: 10.1161/HYPERTENSIONAHA.114.03312. Epub 2014 Apr 21.

15.

Elastin fragmentation in atherosclerotic mice leads to intraplaque neovascularization, plaque rupture, myocardial infarction, stroke, and sudden death.

Van der Donckt C, Van Herck JL, Schrijvers DM, Vanhoutte G, Verhoye M, Blockx I, Van Der Linden A, Bauters D, Lijnen HR, Sluimer JC, Roth L, Van Hove CE, Fransen P, Knaapen MW, Hervent AS, De Keulenaer GW, Bult H, Martinet W, Herman AG, De Meyer GR.

Eur Heart J. 2015 May 1;36(17):1049-58. doi: 10.1093/eurheartj/ehu041. Epub 2014 Feb 19.

16.

Pathophysiology of diastolic dysfunction in chronic heart failure.

Segers VF, De Keulenaer GW.

Future Cardiol. 2013 Sep;9(5):711-20. doi: 10.2217/fca.13.53. Review.

PMID:
24020672
17.

Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial.

Maggioni AP, Greene SJ, Fonarow GC, Böhm M, Zannad F, Solomon SD, Lewis EF, Baschiera F, Hua TA, Gimpelewicz CR, Lesogor A, Gheorghiade M; ASTRONAUT Investigators and Coordinators.

Eur Heart J. 2013 Oct;34(40):3117-27. doi: 10.1093/eurheartj/eht342. Epub 2013 Sep 2.

18.

Cardiotoxicity associated with cancer therapy: pathophysiology and prevention strategies.

Adão R, de Keulenaer G, Leite-Moreira A, Brás-Silva C.

Rev Port Cardiol. 2013 May;32(5):395-409. doi: 10.1016/j.repc.2012.11.002. Epub 2013 Apr 24. Review. English, Portuguese.

PMID:
23623503
19.

Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial.

Gheorghiade M, Böhm M, Greene SJ, Fonarow GC, Lewis EF, Zannad F, Solomon SD, Baschiera F, Botha J, Hua TA, Gimpelewicz CR, Jaumont X, Lesogor A, Maggioni AP; ASTRONAUT Investigators and Coordinators.

JAMA. 2013 Mar 20;309(11):1125-35. doi: 10.1001/jama.2013.1954. Erratum in: JAMA. 2013 Apr 10;309(14):1461.

PMID:
23478743
20.

Treatment of anemia with darbepoetin alfa in systolic heart failure.

Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, Maggioni AP, McMurray JJ, O'Connor C, Pfeffer MA, Solomon SD, Sun Y, Tendera M, van Veldhuisen DJ; RED-HF Committees; RED-HF Investigators.

N Engl J Med. 2013 Mar 28;368(13):1210-9. doi: 10.1056/NEJMoa1214865. Epub 2013 Mar 10.

Supplemental Content

Loading ...
Support Center